Pages that link to "Q44545760"
Jump to navigation
Jump to search
The following pages link to Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. (Q44545760):
Displaying 50 items.
- Adenosine A 2A receptor antagonist istradefylline for levodopa-induced complications in Parkinson's disease (Q24201502) (← links)
- Adenosine receptors as therapeutic targets (Q24632095) (← links)
- Available and emerging treatments for Parkinson’s disease: a review (Q24633444) (← links)
- The A(2A)-adenosine receptor: a GPCR with unique features? (Q24653743) (← links)
- Adenosine A2A receptors in ventral striatum, hypothalamus and nociceptive circuitry implications for drug addiction, sleep and pain (Q24676705) (← links)
- Adenosine A2A and dopamine D2 heteromeric receptor complexes and their function (Q28261240) (← links)
- Highlights on the development of A(2A) adenosine receptor agonists and antagonists (Q28279556) (← links)
- Interactions between metabotropic glutamate 5 and adenosine A2A receptors in normal and parkinsonian mice (Q28589507) (← links)
- Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease (Q29346490) (← links)
- Adenosine A(2A) Receptor Antagonists and Parkinson's Disease (Q29346492) (← links)
- Mutation in ADORA1 identified as likely cause of early-onset parkinsonism and cognitive dysfunction. (Q29347530) (← links)
- G protein-coupled receptor heterocomplexes in neuropsychiatric disorders. (Q30385233) (← links)
- Caffeine and progression of Parkinson disease (Q30432945) (← links)
- Computer-assisted image analysis of caveolin-1 involvement in the internalization process of adenosine A2A-dopamine D2 receptor heterodimers (Q33218797) (← links)
- Methylxanthines, seizures, and excitotoxicity. (Q34154555) (← links)
- A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Single Enantiomer ( )-Mefloquine Compared with Racemic Mefloquine in Healthy Persons (Q34341756) (← links)
- Adenosine A2A receptor antagonist istradefylline 20 versus 40 mg/day as augmentation for Parkinson's disease: a meta-analysis (Q34414817) (← links)
- Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). (Q34756419) (← links)
- Preclinical jockeying on the translational track of adenosine A2A receptors (Q34777609) (← links)
- Functional models of Parkinson's disease: a valuable tool in the development of novel therapies (Q34916732) (← links)
- Pathophysiological roles for purines: adenosine, caffeine and urate (Q35008049) (← links)
- Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease. (Q35489240) (← links)
- Plasticity of purine release during cerebral ischemia: clinical implications? (Q35644634) (← links)
- Asian perspectives on the recognition and management of levodopa 'wearing-off' in Parkinson's disease (Q35781883) (← links)
- Adenosine A2A receptor in the monkey basal ganglia: ultrastructural localization and colocalization with the metabotropic glutamate receptor 5 in the striatum (Q35917127) (← links)
- Purinergic-receptor oligomerization: implications for neural functions in the central nervous system. (Q35950883) (← links)
- A(2A) Receptor Antagonism and Dyskinesia in Parkinson's Disease (Q36057652) (← links)
- Adenosine and brain function (Q36083482) (← links)
- Other pharmacological treatments for motor complications and dyskinesias (Q36094528) (← links)
- Novel pharmacological strategies for motor complications in Parkinson's disease (Q36120761) (← links)
- Adenosine A2A receptor antagonists for Parkinson's disease: rationale, therapeutic potential and clinical experience (Q36172464) (← links)
- New therapeutic approaches to Parkinson's disease including neural transplants. (Q36225073) (← links)
- Treatment of Parkinson's disease : what's on the horizon? (Q36249210) (← links)
- The adenosine kinase hypothesis of epileptogenesis (Q36515651) (← links)
- Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: keys to success and roads to failure (Q36549794) (← links)
- Levodopa, motor fluctuations and dyskinesia in Parkinson's disease (Q36573882) (← links)
- Emerging drugs for Parkinson's disease (Q36580572) (← links)
- Novel pharmacological targets for the treatment of Parkinson's disease (Q36610996) (← links)
- Drug Insight: new drugs in development for Parkinson's disease (Q36631654) (← links)
- Intramembrane receptor-receptor interactions: a novel principle in molecular medicine. (Q36635157) (← links)
- GABAergic circuits in the basal ganglia and movement disorders (Q36820627) (← links)
- Adenosine A(2A) receptors in Parkinson's disease treatment (Q36973390) (← links)
- Pharmacological treatment of Parkinson's disease: life beyond dopamine D2/D3 receptors? (Q37077360) (← links)
- Current status of symptomatic medical therapy in Parkinson's disease (Q37131229) (← links)
- Preventing and controlling dyskinesia in Parkinson's disease--a view of current knowledge and future opportunities (Q37264464) (← links)
- Non-dopaminergic treatments in development for Parkinson's disease (Q37291597) (← links)
- Targets for neuroprotection in Parkinson's disease (Q37302453) (← links)
- Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease (Q37348458) (← links)
- Dual-target-directed drugs that block monoamine oxidase B and adenosine A(2A) receptors for Parkinson's disease (Q37358676) (← links)
- Treatment of Parkinson's disease: what's in the non-dopaminergic pipeline? (Q37506507) (← links)